Equities researchers at Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $135.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 17.64% from the stock’s current price.
The analysts wrote, “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).””
A number of other research analysts have also recently issued reports on GWPH. Goldman Sachs Group Inc initiated coverage on GW Pharmaceuticals PLC- in a report on Friday, January 13th. They issued a “buy”